Eurofins Alphora, Alphora Research Growth, Revenue, Number of Employees and Funding

Overview

Location:
Toronto, ON Canada
Total Funding:N/A
Industry:Pharma
Founded:2003
Lead Investor(s):N/A
Press

Estimated Revenue & Financials

  • Eurofins Alphora, Alphora Research's estimated revenue is currently $22.1M per year.
  • Eurofins Alphora, Alphora Research's estimated revenue per employee is $166241

Employee Data

  • Eurofins Alphora, Alphora Research has 133 Employees.
  • Eurofins Alphora, Alphora Research grew their employee count by 19% last year.
  • Eurofins Alphora, Alphora Research currently has 1 job openings.

What Is Eurofins Alphora, Alphora Research?

Eurofins Alphora (Alphora Research Inc.) is an FDA-approved contract development and manufacturing organization (CDMO) focused on process chemistry, cGMP scale-up, and analytical method development for niche and complex, small molecule active pharmaceutical ingredients (APIs). Our services have supported numerous IND-enabling, clinical, and commercial API technology development programs for pharmaceutical and biotechnology industry clients over the past 15 years. We are currently staffed by 140+ experienced scientific chemists, engineers, chemical operators, business development and support staff. Our 74,000+ ft² facilities include: - Synthetic organic laboratories - cGMP analytical laboratories - cGMP kilo laboratories - cGMP manufacturing plants - cGMP warehouse - cGMP stability chambers - non-GMP and cGMP high potency laboratories Alphora's talented and experienced staff work closely with clients to provide phase-appropriate solutions to balance their immediate and long-term development needs.

keywords:N/A

133

Number of Employees

$22.1M

Revenue (est)

1

Current Jobs

19%

Employee Growth %

N/A

Total Funding

N/A

Valuation

N/A

Accelerator

N/A

Type

Similar Companies

NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
Turnkey Modular...
$5.8M3530%
HLS Therapeutic...
$7M4114%
PharmEng Techno...
$27.1M15713%
Allphase Clinic...
$7M3712%
Janssen
$1342.5M71657%
Fresenius Kabi ...
$19.8M10821%
Everest Clinica...
$26.9M16418%
Robarts Clinica...
$41.4M24014%
Novapharm Limit...
N/A932%
Dalton Pharma S...
$23.1M1254%